Huysseune Sandra, Kienlen-Campard Pascal, Octave Jean-Noël
Université Catholique de Louvain, Center for Neurosciences, Laboratoire de Pharmacologie (FARL 5410), Avenue Hippocrate 54, B-1200 Brussels, Belgium.
Biochem Biophys Res Commun. 2007 Sep 21;361(2):317-22. doi: 10.1016/j.bbrc.2007.06.186. Epub 2007 Jul 17.
The APP intracellular domain (AICD) could be involved in signaling via interaction with the adaptor protein Fe65, and with the histone acetyl transferase Tip60. However, the real function of AICD and Fe65 in regulation of transcription remains controversial. In this study, the human APPGal4 fusion protein was expressed in CHO cells and the transcriptional activity of AICDGal4 was measured in a luciferase-based reporter assay. AICDGal4 was stabilized by expression of Fe65 and levels of AICDGal4 controlled luciferase activity. On the contrary, when human APP was expressed in CHO cells, coexpression of Fe65 increased luciferase activity without affecting the amount of AICD fragment. AICD produced from APP was protected from degradation by orthophenanthroline, but not by lactacystine, indicating that AICD is not a substrate of the chymotryptic activity of the proteasome. It is concluded that Fe65 can control luciferase activity without stabilizing the labile AICD fragment.
淀粉样前体蛋白细胞内结构域(AICD)可能通过与衔接蛋白Fe65以及组蛋白乙酰转移酶Tip60相互作用参与信号传导。然而,AICD和Fe65在转录调控中的实际功能仍存在争议。在本研究中,人APPGal4融合蛋白在CHO细胞中表达,并在基于荧光素酶的报告基因检测中测量AICDGal4的转录活性。Fe65的表达使AICDGal4稳定,且AICDGal4的水平控制着荧光素酶活性。相反,当人APP在CHO细胞中表达时,Fe65的共表达增加了荧光素酶活性,而不影响AICD片段的量。由APP产生的AICD受到邻菲罗啉的保护而不被降解,但不受乳胞素的保护,这表明AICD不是蛋白酶体胰凝乳蛋白酶活性的底物。得出的结论是,Fe65可以控制荧光素酶活性,而无需稳定不稳定的AICD片段。